Targeted cancer-specific gene therapy is a promising strategy for treating metastatic lung cancer, which is a leading cause of lung cancer-related deaths. Previously, we developed a cancer-targeted gene therapy expression system with high tumor specificity and strong activity that selectively induced lung cancer cell killing without affecting normal cells in immunocompromised mice. Here, we found this cancer-targeted gene therapy, SV-BikDD composed of the survivin promoter in the VISA system to drive the apoptotic gene BikDD not only caused cytotoxic effects in cancer cells but also elicited a cancer-specific cytotoxic T lymphocyte response to synergistically increase the therapeutic effect and further develop an effective systemic antitumoral immunity against re-challenges of tumorigenic dose of parental tumor cells inoculated at distant sites in immunocompetent mice. In addition, this cancer targeted gene therapy does not elicit an immune response against normal tissues, but CMV-BikDD treatment does. The therapeutic vector could also induce proinflammatory cytokines to activate innate immunity and provide some benefits in anti-tumor gene therapy. Thus, the current study provides a promising strategy with benefit of antitumoral immune response worthy of in clinical trials for treating lung cancer via cancer-targeted gene therapy.
INTRODUCTION
Lung cancer is the most common cause of cancer deaths worldwide, and the metastatic form of the disease is a major cause leading to mortality (1) . Targeted gene therapy is considered as a novel strategy for treating metastasized cancer or therapy refractory tumors owing to the benefit of tumor-specific expression of therapeutic genes including an apoptosis-inducing gene to kill the tumor cells by a cancer-specific promoter (2) . The success of this strategy also depends on suitable vectors that can efficiently deliver a therapeutic gene into target cells with minimal toxicity. However, most of the identified cancer-specific promoters that do exhibit a high level of cancer specificity are still much weaker than the non-specific strong cytomegalovirus (CMV) promoter (3) . To overcome this issue, a promoter amplification system called VP16-GAL4-WPRE integrated systemic amplifier (VISA) was developed to amplify the cancer-specific promoter activity and the activity in some cancer cell lines are even able to reach a level comparable to that of CMV in cancer cells yet remains inactive in normal tissues (4) .
Previously, we demonstrated that a lung cancer-specific promoter, survivin, is highly active in lung cancer cells but not in other cell types, including immortalized normal cell lines (5) . Briefly, survivin is a member of the inhibitor of apoptosis (IAP) gene family that mediates several anti-apoptotic functions (6, 7) , and its expression is associated with disease progression and poor prognosis in many cancer types (8) . Moreover, survivin has also been implicated in the development of resistance to apoptosis-inducing agents (9) and promotion of metastasis (10) . We integrated the survivin promoter into the VISA system to selectively enhance the expression of a therapeutic gene, BikDD, a mutant form of the pro-apoptotic Bcl2 interacting killer (Bik), to generate survivin-VISA-BikDD (SV-BikDD) and demonstrated that systemic treatment with SV-BikDD DNA in liposome complexes controlled tumor growth and significantly prolonged survival in immunocompromised mice with metastatic human lung cancer and produced virtually no toxicity compared with the CMV promoter vector (5) .
Since immune response is also considered critical for determining the success or failure of gene therapy clinical trials, we further examined the role of immune response elicited under SV-BikDD gene therapy in immunocompetent mice with lung cancer. Here, we show that SV-BikDD cancer-targeted gene therapy not only stimulated innate immunity to provide advantages in anti-tumor treatment but also elicited a cytotoxic T lymphocyte (CTL) response to increase the therapeutic effect and protect against highly aggressive syngeneic TC-1 lung cancer when challenged again in animals, suggesting that SV-BikDD gene therapy can elicit cancer-specific immunity and confer protection against lung cancer. Thus, the current study provides a promising cancer-targeted gene therapy worthy of further development in clinical trials for treating lung cancer, especially the metastatic form of the disease.
MATERIALS AND METHODS
Cell Line. The mouse lung cancer cell line TC-1, which was obtained by cotransformation of HPV-16 E6/E7 and activated ras oncogene to primary mouse lung epithelial cells of C57BL/6 was kindly provided by T. C. Wu (11) Evaluation of Promoter Activity and Cytotoxicity. All the plasmids used in this study were constructed as previously described (5) . To test promoter activity, we used dual-luciferase reporter assay (Promega, Madison, WI) to normalize transfection efficiency according to the manufacturer's instructions. Transfection of the promoter reporter plasmid was carried out with pRL-TK as an internal control for transfection efficiency. The dual-luciferase ratio was presented as the luciferase activity of the tested plasmids divided by the luciferase activity of pRL-TK. For determining cytotoxicity, pRL-TK was also used as a reporter gene in all experiments.
Lung Cancer Animal Model. Female C57BL/6 mice purchased from BioLASCO (Taiwan), at 6-8 weeks of age, were used for syngeneic lung cancer animal model. Mice were maintained in a specific pathogen-free environment in compliance with institutional policy and approved by the Laboratory Animal Care and Use Committee of the China Medical University (Protocol # 98-199-N). Each group has over 5 mice and each experiment was repeated. TC-1 murine lung cancer cells (1 x 10 6 ) were inoculated in C57BL/6 mice through intravenous injection to establish an experimental metastatic lung cancer animal model (12) . Therapeutic plasmids were purified with an Endo-free Mega Prep Kit (Qiagen, Valencia, CA) according to the commercial protocol. Plasmid DNA was dissolved in endotoxin-free TE buffer, and the amount of endotoxin was determined to be less than 10 endotoxin units/mg of DNA by a chromogenic Limulus amoebocyte clotting assay (QCL-1000 kit, BioWhittaker, Walkersville, MD). HLDC (Hung Lab-modified DOTAP:Cholesterol) was produced in our laboratory according to Dr. Nancy Templeton's protocol (13) . Plasmid DNA/HLDC complexes were prepared as previously described (3) . Briefly, HLDC (20 mM) stock solution and stock DNA solution were diluted in 5% dextrose in water (D5W) and mixed in equal volumes to make a Cytotoxic T lymphocyte Assay. Cytolytic activity was measured by standard 4-h chromium release assay as previously described (15) . In brief, every two weeks after the last treatment, 
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Cancer-specific targeting of survivin promoter to TC-1 cells in vitro and in vivo
To assess whether the host immune system plays some roles in our cancer-targeted gene therapy, a mouse lung cancer cell line, TC-1, was used to establish syngeneic lung cancer animal model in immunocompetent mice (11) . Using a series of expression vectors that were previously constructed (5) to drive expression of luciferase ( Fig. 1a; top), we found that survivin combined with VISA system consistently enhanced the survivin promoter activity in TC-1 lung cancer cells. Specifically, survivin-VISA exhibited a 17-fold increase in promoter activity compared with the survivin promoter alone, but the increase in activity was only about half of the CMV promoter ( Fig.1a; bottom) . To further examine whether the activity and specificity of survivin-VISA (SV) is still retained in vivo, luciferase expression constructs driven by CMV and SV (Fig. 1a) complexed with liposomes were administered to tumor-free (without cancer cell inoculation) and tumor-bearing (with cancer cell inoculation) C57BL/6 mice via intravenous injection (Fig. 1b) . Bioluminescent imaging revealed a strong signal in the thoracic area of mice treated with CMV-Luc construct in both tumor-free and tumor-bearing mice, but a low signal was observed in mice treated with SV-Luc construct (Fig. 1b, upper panel) . There was no signal observed from other areas of the body of the mice.
To precisely monitor the source of signal, these mice were sacrificed immediately after imaging, and their organs were dissected for ex vivo imaging (Fig. 1b, lower panel) .
Quantified photon signal showed high values in CMV-Luc-but not SV-Luc-treated groups in the lungs of tumor-free and tumor-bearing mice. Consistent with ex vivo imaging, immunohistochemical analysis also showed strong luciferase expression in both normal lung and tumor tissues in the CMV-Luc-injected group with an intensity score of 1+ and 3+, respectively, while in the SV-Luc-injected group the signal was only detectable in tumor tissues with intensity score 2+, but with intensity score 0 in normal lung tissue by a pathologist's judgment (Fig. 1c) . The IHC results demonstrate a positive signal in both normal and tumor tissue in the CMV-Luc-injected group (Fig. 1c) , thus it caused both strong bioluminescence imaging in tumor-free and tumor-bearing mice (Fig. 1b) . However, there was only a strong signal in tumor tissue and no signal in normal tissue in SV-Luc-injected group (Fig. 1c) . Since the luciferase signal was only located in the tumor nodules that were in a small part of the lungs and not all, the overall bioluminescence imaging in lungs reflect slightly higher in SV-Luc injected tumor bearing mouse compared to tumor-free mouse, but is incomparable to CMV-Luc-injected group. Together, consistent with our previous study (5), the in vivo data here also demonstrated that survivin-VISA-vector-driven transgene expression is more lung cancer specific than CMV vector and appears to be suitable for gene therapy in syngeneic lung cancer animal model in immunocompetent mice.
SV-BikDD treatment inhibited mouse lung cancer cells growth in vitro and ex vivo
As mentioned above, we have previously designed a therapeutic vector that expresses a potent inducer of apoptosis, BikDD, for lung cancer. Bik mutants, BikDD in which threonine 33 and/or serine 35 were changed to aspartic acid to mimic the phosphorylation at these two residues, enhanced their binding affinity with the antiapoptotic proteins Bcl-XL and Bcl-2 and were more potent than wild-type Bik in inducing apoptosis and inhibiting cell proliferation in various human cancer cells (20) . BikDD expression increased the protein level of cleaved caspase-3, which is one of the key executioners of apoptosis by Western Blot (Supplementary Figure 1) . To determine the cytotoxicity effect of the therapeutic plasmids in mouse lung cancer cells, three treatments, SV (vector control without the BikDD gene), CMV-BikDD, and SV-BikDD were used to determine therapeutic effect in vitro and ex vivo.
We first co-transfected TC-1 cells transiently with these plasmids plus pRL-TK (internal control) and measured the relative luciferase activity with the control vector set at 100%. In vitro cytotoxicity assay showed that SV-BikDD nearly killed more than 80% of TC-1 cells as indicated by the loss of luciferase activity compared with the control (Fig. 2a) . We then subcutaneously inoculated TC-1 cells that were transiently transfected with therapeutic plasmids in vitro and measured the tumor volume in C57BL/6 mice (Fig. 2b) . Tumors removed from mice in each group on day 33 clearly demonstrated that pretreatment of TC-1 cells with SV-BikDD significantly reduced tumor growth in mice compared with untreated cells (Fig. 2b, lower panel) . Interestingly, although in vitro cytotoxicity assay (Fig. 2a) showed that CMV-BikDD exhibited better cell killing effect than SV-BikDD, the reverse was observed in the ex vivo experiment in which pretreatment of SV-BikDD showed stronger tumor growth suppression than CMV-BikDD. In addition, mice that received cells pretreated with SV also showed significant initial tumor suppression with smaller tumor size than untreated group before day 25 post tumor inoculation (P < 0.01), suggesting that our VISA cassette might play a role in stimulating host immune response which in turn inhibits tumor growth and may partially explain the differential killing effect we observed between SV-BikDD and CMV-BikDD in vitro and ex vivo.
SV-BikDD inhibited tumor growth and prolonged mice survival time in an experimental metastatic lung cancer animal model
To evaluate the antitumor effect of SV-BikDD treatment in mouse suffering from metastatic lung cancer, TC-1 cells were intravenously injected to mimic metastatic circulating cancer cells in immunocompetent mice which were then given treatment by systemic delivery of liposome:DNA complexes one week later for a total of six treatments. On day 35 after tumor inoculation, fewer lung tumor nodules were found in mice from SV, CMV-BikDD, and SV-BikDD treatment groups compared with uncountable nodules in the lungs of PBS-treated mice (P < 0.01) (Fig. 3a) . While SV, CMV-BikDD, and SV-BikDD treatment all prolonged survival time compared with PBS treatment (P < 0.01), mice from CMV-BikDD-and SV-BikDD-treated groups still had significantly longer survival time than SV group (P < 0.05) (Fig. 3b) . Overall, mice that were administered SV-BikDD maintained a 20% survival rate over 17 months but not in the other treatment groups.
Targeted gene therapy elicits cancer-specific immune response
Next, we determined whether any cancer-specific immunity was elicited by our (Fig. 4c) . In the first detection point at two weeks after last treatment, we observed a significant increase in specific CTL activity directed against TC-1 cells from mice in the SV and SV-BikDD groups, but only a slight increase in the CMV-BikDD group compared with those from naive mice. However, in the second detection point at four weeks after last treatment, all of the treatment groups showed significantly increased CTL activity, suggesting that CTL activity against TC-1 cells in CMV-BikDD group was elicited more slowly than SV-BikDD group. These results indicate that both SV and SV-BikDD vectors induced tumor-specific cytotoxic activities faster than CMV-BikDD.
Since survivin protein is overexpressed in TC-1 tumor but not in normal lung tissue, it can serve as cancer-specific antigen (Fig. 4d, Western blot) . A study recently identified a survivin-derived H-2K b -restricted CTL epitopes that could inhibit tumor growth in mouse model (17) . We used the survivin-derived peptides as stimulator to activate survivin-specific T cell population in the splenocytes in ELISpot assay. The result showed that survivin peptides induced a higher number of IFN-secreting T cells in SV-BikDD-treated mice compared to naive mice (Fig. 4d) . Together, the results from both IFN- ELISpot assay from TC-1 cells and survivin peptide stimulation demonstrated that SV-BikDD treatment could induce stronger cancer-specific T cell immunity than CMV-BikDD treatment.
SV-BikDD does not elicit T cell response against normal cells, but elicit anti-tumor immunity to protect secondary tumor challenge
Previous study indicated that CMV-BikDD treatment caused cytotoxicity in normal using normal lung cells, we showed that CMV-BikDD also induced a substantial increase in IFN-secreting T cells against these normal cells (Fig. 5b) . The results indicate that CMV-BikDD treatment induced stronger immunity against normal cells than other treatments.
The ability of the immune system to respond more strongly to the exposure of the same antigen is a hallmark of T cell-mediated immunity. To test whether the anti-tumoral immunity in the treated animals provides any protection against secondary tumor challenge, TC-1 cells were inoculated again subcutaneously after the treatment course in mice bearing circulating tumor cells on day 35 (Fig. 5c ). All animals in the naive group, which never received any tumor injection prior to implantation of subcutaneous tumors at the challenge sites, demonstrated a tumorigenic dose of 5 x 10 5 TC-1 cells. In CMV-BikDD and SV-BikDD treatment groups, the percentage of tumor-free mice was over 50%, which was significantly higher than that of the naive group on day 50 after first cancer cells inoculation. Moreover, the tumor volume measured at the challenge site in mice was smaller in CMV-BikDD and SV-BikDD treatment groups compared with the naive and SV groups (Fig. 5d) . These results indicate that mice gained protection against secondary distant site tumor challenge after administering cancer-targeted gene therapy.
Induction of innate immunity by gene therapy
To investigate whether the therapeutic plasmids containing CpG motifs stimulate innate immunity in host and mediate tumor remission, we analyzed the levels of proinflammatory cytokines from the serum after intravenous administration of plasmids in immunocompetent mice. The frequency of CpG motifs was similar in SV, CMV-BikDD, and SV-BikDD with 19, 17, and 19 in each plasmid, respectively (Fig. 6a) . The proinflammatory cytokines, IL-6, MCP1, IFN-, TNF, and IL-12 were elicited quickly 8 hours after DNA inoculation for all three plasmids, but these cytokines decreased to basal level after 24 hours (Fig. 6b) . In contrast, IL-10 level did not change significantly between 8 and 24 hours after injection.
These results suggest that all three plasmids could elicit proinflammatory cytokines to activate innate immunity and provide some benefits in anti-tumor gene therapy.
DISCUSSION
Here, we report that the cancer-targeted SV-BikDD system, which selectively enhanced BikDD expression to induce apoptosis in lung cancer cells, also elicited host anti-tumor immunity to synergistically block tumor growth in a syngeneic lung cancer animal model.
The results demonstrate that SV vector without apoptotic gene expression has therapeutic effect through eliciting anti-tumor immunity (Fig. 2b, 3 and 4) . We proposed that the expression of exogenous protein from the VISA vector such as Gal4-VP16 fusion protein might serve as an tumor antigen in cancer cells (21) . Similar observations were noted in which cancer cell lines modified to express foreign protein such as EGFP and -galactosidase elicited cellular anti-tumor immunity when transplanted into immunocompetent mice (22) (23) (24) .
In addition, the presence of CpGs within DNA sequences has also been linked to stimulation of the mammalian immune system. One study has shown that this form of anti-tumor immunity can be generated using null vector approaches through activation of the innate immune system (25) . Moreover, a rapid elevation in the serum proinflammatory cytokines in mice after systemic delivery of liposome:DNA complexes within 8 hr, followed by a reduction ( Figure 6 ) also indicated the innate immune response elicited post treatment (26).
These observations partially explained why treatment even with just vector alone led to a certain reduction of tumor growth compared with the untreated group. Furthermore, our cancer-targeted gene therapy may provide a similar function as cancer vaccine by introducing a surrogate antigen, Gal4-VP16 protein, driven by a cancer-specific promoter in cancer cells to raise anti-tumor immunity. This strategy would also prevent injury to normal tissue in response to the exogenous antigen expression due to control by the cancer-specific promoter.
While previous reports have found that apoptotic cells alone were not sufficient to 
